| 摘要: |
| 钠-葡萄糖共转运体(sodium glucose co-transporter,SGLT)是葡萄糖吸收的载体之一,通过抑制其活性可抑制葡萄糖的重吸收。人体内主要存在SGLT1及SGLT2两种载体,由于SGLT2分布的特异性及重吸收葡萄糖的高效性,SGLT2抑制剂成为葡萄糖治疗的新途径。大量的动物实验及临床研究发现SGLT2抑制剂能显著降低血糖、减轻体质量,但是目前关于SGLT2的临床研究还比较局限,仍面临着安全性、有效性及适应证方面的问题,尚待进一步探讨。 |
| 关键词: 钠-葡萄糖共转运体 钠-葡萄糖共转运体2抑制剂 糖尿病 |
| DOI：10.3724/SP.J.1008.2011.0435 |
| 投稿时间：2010-08-05修订日期：2011-01-05 |
| 基金项目: |
|
| Na+-glucose cotransporter inhibitor for treatment of diabetes |
| ZHANG Zhi-jia,QU Shen* |
| (Department of Endocrinology, Tenth People’s Hospital of Shanghai, Tongji University School of Medicine,Shanghai 200072,China) |
| Abstract: |
| Sodium glucose co-transporter (SGLT) is one of the transporters responsible for the resorption of glucose, and inhibition of its activity can decrease the resorption of glucose. Human SGLT is mainly composed of SGLT1 and SGLT2. Due to the specific distribution and the high efficiency of SGLT2, SGLT2 inhibitor is a potential new strategy for treatment diabetes. Abundant animal experiments and clinical trails have found that SGLT2 inhibitor can greatly lower the blood glucose and help to lose weights. However, the current researches about SGLT2 inhibitor are still very limited both in depth and in broadness; problems concerning the safety, efficacy and indication of SGLT2 inhibitor still need to be further studied. |
| Key words: sodium glucose co-transporter sodium glucose co-transporter-2 inhibitor diabetes mellitus |
